Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database
Abstract Background Belatacept is a co-stimulation blocker used in kidney transplant recipients to prevent allograft rejection. Unlike calcineurin inhibitors, belatacept is non-nephrotoxic and may carry a lower risk of cardiovascular and metabolic complications. However, the European Medicines Agenc...
Saved in:
| Main Authors: | Alexandre O. Gérard, Diane Merino, Nouha Ben Othman, Alexandre Destere, Delphine Viard, Elliot Ewig, Fanny Rocher, Antoine Sicard, Milou-Daniel Drici |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-025-00972-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of belatacept in kidney transplantation
by: N. N. Babenko, et al.
Published: (2018-09-01) -
BELATACEPT IN RENAL TRANSPLANTATION
by: A. I. Sushkov, et al.
Published: (2013-03-01) -
One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients
by: Charlotte Duneton, et al.
Published: (2025-06-01) -
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future
by: Johan Noble, et al.
Published: (2025-05-01) -
Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective
by: Hany M. El Hennawy, et al.
Published: (2025-08-01)